HUP0402282A2 - Triazolo[1,5-a]kinolin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények - Google Patents

Triazolo[1,5-a]kinolin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0402282A2
HUP0402282A2 HU0402282A HUP0402282A HUP0402282A2 HU P0402282 A2 HUP0402282 A2 HU P0402282A2 HU 0402282 A HU0402282 A HU 0402282A HU P0402282 A HUP0402282 A HU P0402282A HU P0402282 A2 HUP0402282 A2 HU P0402282A2
Authority
HU
Hungary
Prior art keywords
branched
straight
alkyl
optionally substituted
halo
Prior art date
Application number
HU0402282A
Other languages
English (en)
Inventor
Péter Arányi
László Balázs
Sándor Bátori
Judit Bence
Kinga Boér
Félix Hajdú
Zoltán Kapui
Endre Mikus
Tibor Szabó
NAGY Lajos T.
Géza Tímári
Katalin Urbán-Szabó
Erzsébet Walcz
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Priority to HU0402282A priority Critical patent/HUP0402282A3/hu
Publication of HUP0402282A2 publication Critical patent/HUP0402282A2/hu
Publication of HUP0402282A3 publication Critical patent/HUP0402282A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)

Abstract

A találmány az (I) általános képletű vegyületekre, ahol R1 jelentésehidrogénatom, vagy 1-4 szénatomos egyenes vagy elágazó szénláncúalkilcsoport; R2 jelentése hidrogénatom, vagy 1-4 szénatomos egyenesvagy elágazó szénláncú alkilcsoport; R3 jelentése hidrogénatom, 1-4szénatomos egyenes vagy elágazó szénláncú alkilcsoport, adott esetbenegy vagy több 1-4 szénatomos egyenes, vagy elágazó szénláncúalkilcsoporttal, 1-4 szénatomos egyenes vagy elágazó szénláncúalkoxicsoporttal, vagy halogénatommal szubsztituált fenil-, tienil-,vagy furilcsoport, adott esetben egy vagy több 1-4 szénatomos egyenes,vagy elágazó szénláncú alkilcsoporttal, 1-4 szénatomos egyenes vagyelágazó szénláncú alkoxicsoporttal, vagy halogénatommal szubsztituált,egy vagy két, vagy három nitrogénatomot tartalmazó 5 vagy 6 tagúheteroaromás gyűrű, vagy egy nitrogénatomot és egy oxigénatomot, vagyegy nitrogénatomot és egy kénatomot tartalmazó 5 tagú heteroaromásgyűrű; R4 és R5 jelentése hidrogénatom, vagy együttesen, adott esetbenmetiléndioxicsoporttal, vagy egy vagy több 1-4 szénatomos egyenes vagyelágazó szénláncú alkilcsoporttal, 1-4 szénatomos egyenes vagy elágazószénláncú alkoxicsoporttal, hidroxicsoporttal vagy halogénatommalszubsztituált 1,3-butadienil-csoport; R6 jelentése hidrogénatom,cianocsoport, aminokarbonilcsoport, 1-4 szénatomosalkoxikarbonilcsoport, vagy karboxicsoport; R7 jelentése hidrogénatom,1-4 szénatomos egyenes vagy elágazó szénláncú alkilcsoport, 1-4szénatomos, adott esetben fenilcsoporttal szubsztituáltalkiléncsoport, adott esetben metilén-dioxi-csoporttal, vagy egy vagytöbb 1-4 szénatomos egyenes, vagy elágazó szénláncú alkilcsoporttal,1-4 szénatomos egyenes vagy elágazó szénláncú alkoxicsoporttal,hidroxicsoporttal, trifluormetilcsoporttal, cianocsoporttal,halogénatommal, amino-, mono- vagy adialkil-amino-csoporttalszubsztituált fenil-, benzil-, tienil-, vagy furilcsoport, vagy adottesetben egy vagy több 1-4 szénatomos egyenes vagy elágazó szénláncúalkilcsoporttal, 1-4 szénatomos egyenes vagy elágazó szénláncúalkoxicsoporttal, vagy halogénatommal szubsztituált, egy vagy két vagyhárom nitrogénatomot tartalmazó 5, vagy 6 tagú heteroaromás gyűrű vagyegy nitrogénatomot és egy oxigénatomot, vagy egy nitrogénatomot és egykénatomot tartalmazó 5 tagú heteroaromás gyűrű, X jelentése -CH2-csoport, -NH- csoport, -NR12- csoport, vagy kénatom vagy oxigénatom,vagy szulfocsoport vagy szulfoxicsoport - ahol R12 jelentése 1-4szénatomos egyenes vagy elágazó szénláncú alkilcsoport, vagy 3-6szénatomos cikloalkilcsoport; n értéke nulla, 1 vagy 2 valamintsóikra, szolvátjaikra, optikailag aktív izomerjeikre és ezek sóira ésszolvátjaira, előállítási eljárásukra, alkalmazásukra és az (I)általános képletű vegyületeket tartalmazó gyógyászati készítményekrevonatkozik. Ó
HU0402282A 2001-12-21 2002-12-17 Triazolo[1,5a] quinoline derivatives, process for their preparation and pharmaceutical compositions containing them HUP0402282A3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HU0402282A HUP0402282A3 (en) 2001-12-21 2002-12-17 Triazolo[1,5a] quinoline derivatives, process for their preparation and pharmaceutical compositions containing them

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0105407A HUP0105407A3 (en) 2001-12-21 2001-12-21 Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HU0402282A HUP0402282A3 (en) 2001-12-21 2002-12-17 Triazolo[1,5a] quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0200143 2002-12-17

Publications (2)

Publication Number Publication Date
HUP0402282A2 true HUP0402282A2 (hu) 2005-02-28
HUP0402282A3 HUP0402282A3 (en) 2007-12-28

Family

ID=90001529

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0105407A HUP0105407A3 (en) 2001-12-21 2001-12-21 Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HU0402282A HUP0402282A3 (en) 2001-12-21 2002-12-17 Triazolo[1,5a] quinoline derivatives, process for their preparation and pharmaceutical compositions containing them

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU0105407A HUP0105407A3 (en) 2001-12-21 2001-12-21 Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates

Country Status (23)

Country Link
US (2) US7365089B2 (hu)
EP (1) EP1456204A1 (hu)
JP (2) JP4724366B2 (hu)
KR (1) KR100934796B1 (hu)
CN (1) CN1307175C (hu)
AU (1) AU2002353240B2 (hu)
BR (1) BR0215276A (hu)
CA (1) CA2470064C (hu)
EA (1) EA007066B1 (hu)
HR (1) HRP20040672A2 (hu)
HU (2) HUP0105407A3 (hu)
IL (2) IL162444A0 (hu)
IS (1) IS7318A (hu)
MA (1) MA27094A1 (hu)
MX (1) MXPA04006113A (hu)
NO (1) NO329757B1 (hu)
NZ (1) NZ534016A (hu)
PL (1) PL370747A1 (hu)
RS (1) RS56004A (hu)
TN (1) TNSN04106A1 (hu)
UA (1) UA79955C2 (hu)
WO (1) WO2003053968A1 (hu)
ZA (1) ZA200404802B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
HUP0400812A2 (en) * 2004-04-19 2006-02-28 Sanofi Aventis Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
US20050288502A1 (en) * 2004-06-25 2005-12-29 Andersen Denise L Substituted heterocyclic compounds and methods of use
CN102702314A (zh) * 2006-11-30 2012-10-03 首都医科大学 具有靶向抗血栓活性的rgdfyigsr、制备和应用
CN102702312A (zh) * 2006-11-30 2012-10-03 首都医科大学 具有靶向抗血栓活性的rgdvyigsk、制备和应用
CN102702315A (zh) * 2006-11-30 2012-10-03 首都医科大学 具有靶向抗血栓活性的rgdsyigsk、制备和应用
CN102702313A (zh) * 2006-11-30 2012-10-03 首都医科大学 具有靶向抗血栓活性的rgdvyigsr、制备和应用
CN102702316A (zh) * 2006-11-30 2012-10-03 首都医科大学 具有靶向抗血栓活性的rgdfyigsk、制备和应用
HUP0700395A2 (en) * 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
DE102007061763A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
DK2950649T3 (da) 2013-02-01 2020-05-04 Wellstat Therapeutics Corp Aminforbindelser med antiinflammations-, antisvampe-, antiparasit- og anticanceraktivitet
CN108358927B (zh) * 2018-01-26 2020-09-01 郑州大学 1,4-二取代1,2,3-三氮唑核苷类似物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE280110C (hu)
DE280109C (hu)
GB1479759A (en) * 1974-11-23 1977-07-13 Lepetit Spa Heterocyclic fused derivatives of indole and quinoline
DD280110A1 (de) * 1989-02-22 1990-06-27 Univ Berlin Humboldt Verfahren zur herstellung von 1.2.4-triazolo/1.5-a/-pyridin-8-carbonitrilen
DD280109A1 (de) * 1989-02-22 1990-06-27 Univ Berlin Humboldt Verfahren zur herstellung substituierter 1.2.4-triazolo/1.5-a/-pyridine
DE3926770A1 (de) 1989-08-12 1991-02-14 Basf Ag (1,2,4)triazolo(1,5-a)pyridine
US6066642A (en) * 1996-01-29 2000-05-23 The United States Of America As Represented By The Department Of Health And Human Services Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
US5780481A (en) * 1996-08-08 1998-07-14 Merck & Co., Inc. Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6355653B1 (en) * 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates

Also Published As

Publication number Publication date
NZ534016A (en) 2005-04-29
ZA200404802B (en) 2005-08-29
MXPA04006113A (es) 2005-06-08
BR0215276A (pt) 2004-12-14
RS56004A (en) 2006-10-27
AU2002353240A1 (en) 2003-07-09
IL162444A0 (en) 2005-11-20
CA2470064C (en) 2010-01-26
HUP0105407A3 (en) 2004-04-28
PL370747A1 (en) 2005-05-30
KR20040072671A (ko) 2004-08-18
EA007066B1 (ru) 2006-06-30
TNSN04106A1 (en) 2006-06-01
JP2011042653A (ja) 2011-03-03
HUP0402282A3 (en) 2007-12-28
EP1456204A1 (en) 2004-09-15
NO329757B1 (no) 2010-12-13
WO2003053968A1 (en) 2003-07-03
JP2005518384A (ja) 2005-06-23
HRP20040672A2 (en) 2005-08-31
NO20043119L (no) 2004-07-20
US7713992B2 (en) 2010-05-11
CN1606556A (zh) 2005-04-13
HUP0105407A2 (hu) 2003-10-28
CN1307175C (zh) 2007-03-28
IL162444A (en) 2010-04-29
JP4724366B2 (ja) 2011-07-13
KR100934796B1 (ko) 2009-12-31
UA79955C2 (en) 2007-08-10
AU2002353240B2 (en) 2008-06-19
IS7318A (is) 2004-06-16
US20080146604A1 (en) 2008-06-19
US7365089B2 (en) 2008-04-29
MA27094A1 (fr) 2004-12-20
HUP0105407D0 (en) 2003-02-28
EA200400848A1 (ru) 2004-12-30
CA2470064A1 (en) 2003-07-03
US20050124648A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
HUP0402282A2 (hu) Triazolo[1,5-a]kinolin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények
AU2003215753A1 (en) Imidazopyridine derivatives as kinase inhibitors
ATE349432T1 (de) 2-anilino-pyrimidin-derivate als cyclin-abhängige kinase hemmer
UA84878C2 (ru) Производные 2-пиридона как ингибиторы нейтрофилов эластазы, фармацевтическая композиция на их основе, способ их получения
EP1548008A4 (en) COMPOUND HAVING BETA-TRANSFORMING GROWTH FACTOR INHIBITORY ACTIVITY AND DRUG CONTAINING COMPOSITION
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
BG103195A (en) Substituted indazole derivatives and their application as inhibitors of phosphodiesterase (pde) type iv and of the production of a tumournecrotic factor (tnf)
IL114894A (en) Pyrrolidine derivatives as endothelin antagonists, pharmaceutical compositions containing them, and their use in the preparation of medicaments
AU2001293233A1 (en) Aza heterocyclic derivatives and their therapeutic use
BR0008770A (pt) Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, processo para a produção de um efeito anti-câncer em um animal de sangue quente, uso de um derivado de pirimidina, e, composição farmacêutica
CA2523261A1 (en) Fused pyrimidine derivatives with crf activity
MY124527A (en) 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
WO2001094345A3 (en) Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
FI970317A0 (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
MX2008001551A (es) Compuestos de 3-aminocarbazol, composicion farmaceutica que los contiene y metodo para la preparacion de los mismos.
DE69332259T2 (de) Kondensierte Thiadiazolderivate, Verfahren zu ihrer Herstellung und deren Verwendung
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
EP0716083A4 (en) BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND INTERMEDIATES THEREOF
BR0208829A (pt) Sal farmaceuticamente aceitável, composto, processos para a preparação de um sal, de um composto e de uma forma cristalina dos compostos, formulação farmacêutica, uso de um composto, e, método de profilaxia ou tratamento de uma arritmia
ATE492548T1 (de) 4-amino-3-arylamino-6-arylpyrazoloä3,4- düpyrimidin-derivate, verfahren zu ihrer herstellung und deren verwendung als antivirale wirkstoffe
NO20004273L (no) Streptograminderivater, deres fremstilling samt preparater inneholdende forbindelsene
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
MXPA03010321A (es) Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina.
SE0102057D0 (sv) New Salts I
CA2412594A1 (en) Pyrazino[1',2':1,6]pyrido[3-4-5] indole derivatives

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees